Back to Newsroom

Ocata Therapeutics Approved for Listing on NASDAQ

MARLBOROUGH, Mass.– Ocata Therapeutics, Inc. (“Ocata”; NASDAQ Global Market: OCAT), a clinical stage biotechnology company developing regenerative ophthalmology therapeutics, today announced that it has received notice that the NASDAQ Listing Qualifications Department has approved its application to list the Company’s common stock on the NASDAQ Global Market, effective with the opening of trading today, February 26, 2015, under the ticker symbol “OCAT”.

Click here to read more